Pharmaceuticals, Life Sciences and Biotechnology
|
|
- Scarlett Cobb
- 7 years ago
- Views:
Transcription
1 Pharmaceuticals, Life Sciences and Biotechnology Sector Fact Sheet 1. Sector Description The Global Industry Classification Standard (GICS) distinguished two main groups in the healthcare industry: Health care equipment and services; and pharmaceuticals, biotechnology and related life sciences. This fact sheet straddles both of these groups, examining medical equipment, medical supplies, private health care services, biotechnology, pharmaceuticals and miscellaneous scientific services. 2. Sector Overview 2.1 Global Sector Overview Currently, the global pharmaceutical market is dominated by United States companies, which accounted for 28 of sales in 21, according to IMap (212). The European Union accounted for nearly 15, and Japan for 12 of the global market. The global pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 5 to 8 through 214. This growth is expected due to accounting for the impact of the changing combinations of innovative and mature products on the market and the rising healthcare access in emerging markets, and on the other hand, the price pressure by regulators in developed countries (IMap, 212). The pharmaceutical sector in emerging markets is expected to grow by 13 in 21 to16 in 215 (IMap, 212). Single-digit growth is forecast for the sector over the next five years due to funding pressures and the dynamics of the innovation cycle. Companies face pressure to adapt to evolving patient needs and long-term trends in the market place. Patent expirations have led to growth in the generic drug market globally, coupled with the rising cost pressure on healthcare. In 21, generic drugs were estimated to cost 3 to 8 less than original medicines. 2.2 South Africa Sector Overview According to Business Monitor International (BMI; 212), South Africa is a fast-emerging pharmaceutical market. The country s pharmaceutical industry is well-developed and mainly focused on the production of generic products, including manufacturing copy drugs under licence. Many multinationals have an established presence in South Africa, many as a base for their Sub- Saharan African operations. Tendering for the public sector is competitive, particularly on price. Top companies include Adcock Ingram and Aspen Pharmaceuticals. Foreign companies operating in the country include Pfizer (United States), GlaxoSmithKline (United Kingdom), Sanofi (France), Bristol Myers Squibb (United States) and Johnson & Johnson (United States). The South African healthcare system consists of the public sector and smaller, fast-growing private companies. The public healthcare sector supplies basic primary services via relevant public institutions. High-tech, complex operations are often only supplied by private sector companies. Almost 5 of South Africa s healthcare expenditure is accounted for by private insurance schemes. Approximately 8 of the population receive public sector healthcare (BMI, 212). The National Health Insurance Scheme is scheduled to start roll-out in 212, and is expected to take 14 years, with the first five years scheduled for the administration and regulatory measures to be put into place. This plan aims to focus on the fundamentals of care administration, management and delivery. In terms of research and development in the sector, many new projects have been established in the past five years. An International Centre for Genetic Engineering and Biotechnology (ICGEB) was established in 27 to pursue research into 1
2 Value (ZARbn) diseases affecting the developing world including African sleeping sickness, bilharzia, malaria and HIV/AIDS. The centre has partner laboratories in Italy and India. The South African drug pricing system is based on a single exit price (SEP) which is determined by the manufacturer price, which the Department of Health decides by looking at a pricing basket of Canada, New Zealand, Spain, Australia and selecting the lowest price. Value-added tax (VAT) and the logistics fee, which are both 1 and15, are added to the price. This is the price at which the drug is sold to the pharmacists, which then calculate what tier the drug s price comes under and adds their own profit margin accordingly, while not going over the maximum mark-up (BMI, 212). In terms of industry developments, the biggest sellers in terms of pharmaceutical sales are treatments for diseases such as heart disease and hypertension which predominantly affect a richer population profile. According to BMI (212), nearly 1 South Africans die of heart attacks or strokes each day, although this figure pales when compared with the 1, people that are estimated to die of AIDS. According to BMI (212), drug spending in South Africa reached ZAR27.19bn in, an annual increase of 9.3 from 21. South Africa s prescription drug market was worth ZAR23.96bn in, and is expected to increase in value to ZAR36.41bn (USD4.55bn) by 216. The prescription drug market accounted for 88.1 of South Africa s total drug market in. It is forecast that increases in the demand for generic prescription drugs in conjunction with slowing demand for prescription drugs and the government policy compelling state organisations to buy some drugs exclusively from domestic suppliers will affect this percentage contribution up until 216 (BMI, 212). PHARMACEUTICAL SALES, * Growth * 213* 214* 215* Value (ZARbn) Change Source: NEDLAC 212, BMI, 212 * Forecasted Values The performances of different drug categories are shown below. Sales of prescription drugs are forecast to continue growing at rates of more than 1 this trend is set to continue until 215. In 212, sales of prescription drugs increased by 1.57, while sales of generic drugs and over-the-counter drugs have grown at and 14.95, respectively. 2
3 Value (ZARbn) Prescription drug sales (ZARbn) Patented drug sales (ZARbn) Generic drug sales (ZARbn) Over-the-counter (OTC) medicine sales (ZARbn) Source: NEDLAC 212, BMI, PERFORMANCE OF DRUG SALES, Consumers spending on prescription sales in South Africa have decreased due to the availability and affordability of over-thecounter (OTC) medicines. Patented medicines represent the largest single segment of the total market (patented, generic and OTC drugs) by value, at just under 59 in, although this share is expected to continue declining going forward (BMI, 212). South Africa s patented drug market was worth ZAR16.2bn (USD2.21bn) in, with this value expected to increase to ZAR22.16bn (USD2.77bn) by 216. The use of patented drugs is buoyed by the ever-present demand for niche medicines. South Africa s generic drug market was worth ZAR7.94bn in and is calculated to increase to ZAR14.25bn (USD1.78bn) by 216, according to BMI (212). Generic drugs share of total medicine sales in South Africa increased to more than 5 in in volume terms. Customers preference for generic drugs is also supported by the fact that many medical aid schemes only cover the cost of generic equivalents. South Africa s OTC medicines market was worth ZAR3.23bn in and is calculated to increase to ZAR4.96bn by 216. The OTC sub-sector is becoming highly competitive with chain pharmaceutical stores like Clicks and DisChem, Over-the-Counter medicines are accessible and cheap, appealing to consumers without adequate medical aid. According to BMI (), genericisation in the prescription drug market will allow the OTC market to gain in its relative share against prescription medicines. South Africa s medical device market was worth ZAR11.43bn (USD1.57bn) in and is calculated to increase in value to ZAR16.43bn (USD2.5bn) by 216. The medical device market accounted for 4.4 of total healthcare spending in and is forecast by BMI (212) to account for 4.1 of total healthcare spending in 216, before falling to 3.8 by 221. Generic drugs 29 BREAKDOWN OF PHARMACEUTICAL SALES, Over-the-counter (OTC) medicines 12 Source: NEDLAC 212, BMI, 212 Patented drugs 59 South Africa s medical device market was valued at USD1.52bn in (BMI, 212) and is dominated by foreign companies. Imports account for 9 of the market by value, an indication of the underdevelopment of the industry. South Africa has successfully transformed nuclear weapons from the apartheid era into medical tools, which could be used to detect cancer and 3
4 heart diseases. The South African Nuclear Energy Corporation (Necsa) formulated a new technique allowing scientists to create molybdenum-99 (MO-99) using low-enriched uranium, instead of the high-enriched type used for making bombs. According to BMI (212), domestic manufacturing mostly remains fragmented and focused on the production of low-tech and low-value devices such as surgical goods and disposable needles. Expensive equipment, such as magnetic resonance imaging (MRI) scanners, is imported, much like in other emerging markets. The developed markets of the United States, European Union and Japan produce virtually all the high-tech medical devices and accounted for 83 of global medical device manufacturing by value, according to a 22 survey by the World Health Organisation Swot Analysis of the South African Pharmaceutical and Healthcare Sector: STRENGTHS WEAKNESSES OPPORTUNITIES THREATS Well established local manufacturing industry, supported by foreign investment. High disease burden ensures a high demand for drugs, especially antiretroviral drugs Winners of government drug tenders are guaranteed substantial revenues. Government procurement schemes favour local drugmakers Largest drug market in Africa, with the fifth highest expenditure on pharmaceuticals per capita Source: BMI, 212 Government pricing policy focused on reducing costs. Ambiguous parallel trade regulations open to abuse Private drug market and threatening multinationals profit margins. Funding shortcomings in the public healthcare system. Lack of universal healthcare insurance, with 2 of population not covered by any insurance schemes. Slow drug approvals process Vast inequality between the provision in the public and private sectors. 2.3 Western Cape Sector Overview Potential for marked generic sector growth, in line with cost containment and the recent introduction of a tiered-pricing structure for pharmacists. Huge market for HIV/AIDS drugs given disease s epidemic levels, tenders favour local companies with high Black Economic Empowerment (BEE) ratings. Rising demand for diabetes and other chronic disease management treatments. Regulatory conditions to improve with new drug registration agency SAHPRA. Growing market for clinical trials due to the country s high infectious disease burden and high number of treatment-naïve patients. An attractive export base into less politically stable Southern African nations particularly with new Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S) membership Rising competition from Indian generic drug producers. State organisations will be compelled to buy some drugs exclusively from domestic suppliers. Some firms may struggle to comply with BEE guidelines in the South African Healthcare charter. Failure to expand and revise medicines reimbursement. Modernisation costs to potentially prohibit harmonisation of domestic regulation with international norms. Price restrictions and proposed benchmarking are likely to lead to a reduction in foreign investment and even result in some companies exiting the market. Rising private health costs threatening to put private health insurance further out of reach of the majority of the population. The Western Cape is a strong market in the biotechnology and medical devices sector, with institutes such as the Biovac Institute forming the cornerstone of the Province s health sector. In addition, the Western Cape hosts one of the highest concentrations of medical device and biotechnology companies, research institutes and research groups in South Africa. This provides an ideal opportunity for further improving the sector s competitiveness and international attractiveness. Cape Town boasts some of the worlds top technology companies in medical devices, with products that are considered top of their class, and unique. The Western Cape Provincial Government, together with the City of Cape Town is testing the feasibility of investing in a health technology park in Cape Town. The objective is to create a strategic clustering of pharmaceutical companies, research institutes and groups, clinical trial facilities and R&D facilities. 4
5 Value 3. Trade 3.1 Global Trade in Pharmaceutical Products The figure below shows the trend in global exports of pharmaceutical products from 22 to. In, exports totalled ZAR3.3bn, an increase of from 21. Imports totalled ZAR15.96bn in, an increase of 5.87 from 21. This is the highest level of imports recorded in the ten-year period from 22 to. GLOBAL EXPORTS OF PHARMACEUTICAL PRODUCTS, Exports Source: TradeMap, 212 The top global exports of pharmaceutical products in were medicament mixtures (ZAR2.4trn), human and animal blood (ZAR643.22bn) and pharmaceutical goods such as specified sterile products sutures and laminaria (ZAR15.93bn). RANK HS CODE TOP GLOBAL EXPORTS OF PHARMACEUTICAL PRODUCTS, PRODUCT (ZARbn) 1 34 Medicament mixtures (not 32, 35, 36), put in dosage Human & animal blood; antisera, vaccines, toxins, micro-organism cultures Pharmaceutical goods, specified sterile products sutures, laminaria Medicament mixtures (not 32, 35, 36) not in dosage Dressings packaged for medical use Glands & extracts, secretions for organotherapeutic uses; heparin TOTAL EXPORTS Source: TradeMap, 212 The top export markets for pharmaceutical products are located primarily in North America and the European Union. The top export markets for pharmaceutical products were Germany (ZAR491.94m), Switzerland (ZAR381.61m) and Belgium (ZAR344.8m). The export performance of the top 1 exporting countries for pharmaceutical products differed extensively in terms of growth in : Exports from Switzerland increased by 15.9 and exports from Ireland increased by Alternatively, exports from the Netherlands declined by 25.86, while exports from the United States declined by 6.24 in. 5
6 TOP 1 EXPORT MARKETS FOR PHARMACEUTICAL PRODUCTS, RANK MARKET SHARE, 1 Germany Switzerland Belgium United States Ireland United Kingdom France Netherlands Italy Spain TOTAL EXPORTS Source: TradeMap, 212 The top import markets for pharmaceutical products are located primarily in North America and the European Union. The top import markets for pharmaceutical products are the United States (ZAR474.77m), Germany (ZAR346.7m) and Belgium (ZAR243.68m). Imports by the Netherlands declined by 4.66 in. TOP 1 IMPORT MARKETS FOR PHARMACEUTICAL PRODUCTS, RANK MARKET SHARE, 1 United States Germany Belgium France United Kingdom Italy Switzerland Japan Netherlands Spain TOTAL IMPORTS Source: TradeMap, South Africa Trade in Pharmaceuticals Products The figure below shows the trend in South Africa s trade in pharmaceutical products from 22 to. South Africa has consistently held a negative trade balance in this sector. In, exports totalled ZAR1.1bn, an increase of from 21. Imports totalled ZAR15.96bn in, an increase of 5.87 from 21. This is the highest level of imports recorded in the tenyear period from 22 to. 6
7 Value (ZARm_ Source: Quantec, SOUTH AFRICA TRADE IN PHARMACEUTICAL PRODUCTS, Exports Imports Trade balance The table below shows the top pharmaceutical products traded by South Africa in. The top exports of pharmaceutical products from South Africa in was medicaments in dosage (ZAR65.31m), medicaments formulated in bulk (ZAR1.56m) and vaccines for veterinary use (ZAR73.97m). In terms of growth in, exports of contraceptive preparations based on hormones or spermicides increased by 88.65, while exports of medicaments formulated in bulk increased by The top pharmaceutical product imports to South Africa in were medicaments in dosage (ZAR1.1bn), vaccines for human use (ZAR1.1bn) and antibiotics in dosage (ZAR889m). RANK TOP 1 EXPORTS FROM SOUTH AFRICA, TOP 1 IMPORTS TO SOUTH AFRICA, PRODUCT (HS6) 21- RANK PRODUCT (HS6) 21-1 H349: Medicaments, in dosage H349: Medicaments, in dosage H339: Medicaments, formulated, in bulk H322: Vaccines, human use H323: Vaccines, veterinary use H342: Antibiotics, in dosage H351: Medical dressings having an adhesive layer H359: Medical dressings except those with adhesive layer H366: Contraceptive preparations based on hormones or spermicides H321: Antisera and other blood fractions H3439: Hormones, except contraceptives, in dosage H339: Medicaments, formulated, in bulk H345: Vitamins, derivatives, in dosage H3431: Insulin, in dosage H3339: Hormones, no antibiotics, bulk, not contraceptive 9 H342: Antibiotics, in dosage H3439: Hormones, except contraceptives, in dosage H323: Vaccines, veterinary use H341: Penicillins and streptomycins, derivatives, in dosage H3432: Adrenal cortical hormones, in dosage TOTAL EXPORTS TOTAL IMPORTS Source: Quantec, 212 7
8 Value 3.2 Western Cape Trade in Pharmaceuticals Products The figure below shows the trend in Western Cape trade in pharmaceutical products from 22 to. The Western Cape has consistently held a negative trade balance in this sector. In, exports totalled ZAR148.41m, an increase of from 21. Imports totalled ZAR2.4bn in, an increase of from 21. This is the highest level of imports recorded in the ten-year period from 22 to. WESTERN CAPE TRADE IN PHARMACEUTICALS PRODUCTS, Source: Quantec, Exports Imports Trade balance The table below shows the top pharmaceutical products traded by the Western Cape in. The top exports of pharmaceutical products from the Western Cape in was medicaments in dosage (ZAR121.9m), medicaments formulated in bulk (ZAR5.8m) and vaccines for veterinary use (ZAR4.55m). The top pharmaceutical product imported by the Western Cape in were medicaments in dosage (1.4bn), vaccines for human use (ZAR439m) and antibiotics in dosage (ZAR145m). RANK TOP 1 EXPORTS FROM THE WESTERN CAPE, TOP 1 IMPORTS TO THE WESTERN CAPE, PRODUCT (HS4) 21- RANK PRODUCT (HS4) 21-1 H349: Medicaments, in dosage H349: Medicaments, in dosage H339: Medicaments, formulated, in bulk H322: Vaccines, human use H323: Vaccines, veterinary use H342: Antibiotics, in dosage H3439: Hormones, except contraceptives, in dosage H345: Vitamins, derivatives, in dosage H366: Contraceptive preparations based on hormones or spermicides H3439: Hormones, except contraceptives, in dosage H341: Penicillins and streptomycins, derivatives, in dosage H3432: Adrenal cortical hormones, in dosage H365: First-aid boxes and kits H323: Vaccines, veterinary use H319: Heparin, salts, for therapeutic use H359: Medical dressings, except those with adhesive layer H329: Blood, toxins, cultures, medical use H339: Medicaments, formulated, in bulk H359: Medical dressings, except those with adhesive layer H364: Dental cements and other dental fillings, bone cements TOTAL TOTAL Source: Quantec, 212 The Western exports pharmaceutical products primarily to markets in Asia, Africa and Europe. The top export markets for pharmaceutical products from the Western Cape are India (ZAR3.66m), Zimbabwe (ZAR14.37m) and France (ZAR12.67m). Exports to Nigeria increased by 2, in, while exports to India increased by 1,
9 TOP 1 EXPORT MARKETS FOR PHARMACEUTICAL PRODUCTS FROM WESTERN CAPE, RANK COUNTRY 21- SHARE, 1 India Zimbabwe France United Kingdom Bangladesh Nigeria Indonesia Myanmar United Arab Emirates Hong Kong TOTAL Source: Quantec, 212 The Western imports pharmaceutical products primarily from North America, Europe and Asia. The top import markets for pharmaceutical products to the Western Cape in were the United States (ZAR69.37m), India (ZAR417.31m) and Ireland (ZAR275.34m). Imports from Canada increased by in TOP 1 IMPORT MARKETS FOR PHARMACEUTICAL PRODUCTS BY WESTERN CAPE, RANK COUNTRY 21- SHARE, 1 United States India Ireland Italy United Kingdom Germany Belgium France China Canada TOTAL Source: Quantec, Foreign Direct Investment (FDI) 4.1 Global FDI Between January 23 and June 212, a total of 5,455 FDI projects were recorded globally, equating to a 3.9 share of global FDI across all sectors. These projects represent a total capital investment of ZAR1,442.1bn, which is an average investment of ZAR m per project. During the period, a total of 528,391 jobs were created in this sector globally. The table below provides a breakdown of FDI into this sector. The most FDI activity was recorded in the pharmaceuticals sector, accounting for 2,391 projects in this period, while medical devices accounted for 1,435 projects, healthcare for 95 projects and biotechnology for 679 projects, globally. 9
10 Value SECTOR PROJECTS CAPEX (ZARbn) BREAKDOWN OF FDI, 23-JUNE 212 AVERAGE CAPEX (ZARbn) JOBS CREATED AVERAGE JOBS COMPANIES Pharmaceuticals Medical Devices Healthcare Biotechnology TOTAL The figure below demonstrates the trend of FDI activity for this group of sectors, from 23 to June 212. FDI peaked in 23, when 799 FDI projects were recorded totalling ZAR213.69m in total capital value. In, 751 projects were recorded, while 285 projects were recorded from January to June 212. FDI PERFORMANCE, 23- JUNE Capex (ZARbn) Projects Projects The top global source markets were the United States (2,331 projects), Germany (423 projects) and the United Kingdom (354 projects). In terms of the capital value of projects, the top source markets were the United Kingdom (44.73 of total capex) and Switzerland (1.73 of total capex). TOP GLOBAL SOURCE MARKETS, 23-JUNE 212 RANK COUNTRY PROJECTS PROJECTS CAPEX (ZARbn) CAPEX COMPANIES COMPANIES 1 United States Germany United Kingdom Switzerland Japan France India Canada Netherlands Denmark Other Countries TOTAL
11 The top global destination markets were the United states (1,373 projects), China (414 projects) and the United Kingdom (325 projects). In terms of the capital value of projects, the top source markets were the United States (24.9 of total capex), China (9.78) and India (7.23). RANK COUNTRY PROJECTS PROJECTS TOP GLOBAL DESTINATION MARKETS, 23-JUNE 212 CAPEX (ZARbn) CAPEX COMPANIES COMPANIES 1 United States China United Kingdom India Germany Ireland France Singapore Spain Russia Other Countries TOTAL The top companies in this sector, measured by FDI activity, are Aspen Dental (95 projects), GlaxoSmithKline (GSK) (78 projects) and Pfizer (64 projects). TOP 1 INVESTING COMPANIES, 23-JUNE 212 RANK INVESTING COMPANY PROJECTS CAPEX (ZARbn) 1 Aspen Dental GlaxoSmithKline (GSK) Pfizer Novartis Euromedic International Sanofi-Aventis AstraZeneca Eisai GE Healthcare Pharmaceutical Product Other companies TOTAL In terms of the sub-sector breakdown of FDI, 35.6 of projects were pharmaceutical preparations, followed by medical equipment and supplies (25.6), biological products (1.61) and medicinal and botanical (5.4). In terms of capex, the top two sub-sectors were pharmaceutical preparations (47.54 of total capex) and medical equipment and supplies (14.29). 11
12 BREAKDOWN OF FDI BY SUB-SECTOR, 23-JUNE 212 Pharmaceutical preparations Medical equipment & supplies Biological products (excluding diagnostics) Medicinal & botanical Outpatient care centres & medical & diagnostic laboratories Offices of physicians, dentists and other medical practicitioners General medical & surgical hospitals Health & personal care stores Nursing & residential care facilities In-Vitro diagnostic substances Electromedical and Electrotherapeutic Apparatus Other (Healthcare) Other (Biotechnology) Unspecified Home healthcare & all other ambulatory health care services Psychiatric & speciality hospitals Capex Projects 4.2 South Africa and Western Cape FDI Inward FDI to South Africa and the Western Cape Between January 23 and June 212, a total of 23 FDI projects were recorded into this sector in South Africa. These projects represent a total capital investment of ZAR5.63bn, which is an average investment of ZAR244.61m per project. During the period, a total of 3,98 jobs were created. 12
13 Value INWARD FDI TO SOUTH AFRICA, 23-JUNE Capex Projects Projects The top source markets were the United Kingdom (8 projects), United States (6 projects) and India and Japan with 2 projects each. In terms of the capital value of projects, the top source markets were the United Kingdom (19.98 of total capex) and Switzerland (3.15 of total capex). TOP 1 SOURCE MARKETS FOR INWARD FDI TO SA, 23-JUNE 212 RANK COUNTRY PROJECTS PROJECTS CAPEX CAPEX COMPANIES COMPANIES 1 United Kingdom United States India Japan Netherlands Singapore Switzerland China France TOTAL In terms of the sub-sector breakdown of FDI, of projects were pharmaceutical preparations, followed by medical equipment and support activities (21.74), biological products (13.4) and medicinal and botanical (8.7). In terms of capex, the top two sub-sectors were pharmaceutical preparations (37.77 of total capex) and medicinal and botanical (34.5). In terms of business activity, 3.43 of projects were manufacturing activities, 26.9 were sales, marketing and support activities and 26.9 were research and development activities. Manufacturing activities accounted for of total capex of projects. 13
14 BREAKDOWN OF FDI BY SUB-SECTOR, 23- JUNE 212 BREAKDOWN OF FDI BY BUSINESS ACTIVITY, 23-JUNE 212 Outpatient care centres & medical & diagnostic laboratories Construction Unspecified Business Services Medicinal & botanical Design, Development & Testing Biological products (excluding diagnostics) Research & Development Medical equipment & support activities Sales, Marketing & Support Pharmaceutical preparations Manufacturing Capex Projects Capex Projects The table below provides a list of the inward projects initiated in the Western Cape in the pharmaceuticals, life sciences and biotechnology sector. The highest-value project was initiated by VIP Healthcare Solutions Limited from the United Kingdom, who initiated the construction of an outpatient care centre and laboratory, employing an initial 29 people. Four projects were initiated in Cape Town and one project in Stellenbosch. DATE INVESTING COMPANY SOURCE COUNTRY INWARD FDI TO THE WESTERN CAPE, 23-JUNE 212 DESTINATION CITY INDUSTRY SECTOR /9 Cryo-Save South Africa Netherlands Cape Town Biotechnology 21/1 GlaxoSmithKline (GSK) United Kingdom Cape Town Pharmaceuticals 21/4 VIP Healthcare Solutions Limited United Kingdom Cape Town Healthcare 25/11 GlaxoSmithKline (GSK) United Kingdom Cape Town Pharmaceuticals 24/9 Alltech United States Stellenbosch Medical Devices SUB-SECTOR Biological products (except diagnostic) Pharmaceutical preparations Outpatient care centres & medical & diagnostic laboratories Pharmaceutical preparations Medical equipment & supplies CLUSTER Life sciences INDUSTRY ACTIVITY Design, Development & Testing JOBS Life sciences Manufacturing Life sciences Construction Life sciences Manufacturing Life sciences Manufacturing TOTAL
15 4.2.2 Outward FDI from South Africa and the Western Cape The table below provides a list of all outward FDI projects initiated by South African companies in this sector, from 23 to June 212. The highest value project was initiated by Network Healthcare Holdings Limited (Netcare) in 29, who initiated the construction of a hospital in the United Kingdom. The Clicks Group, based in the Western Cape, invested in 3 retail projects in the health and personal care stores sub-sector, in Swaziland (), Botswana () and Lesotho (212). DATE INVESTING COMPANY 212/4 Clicks Group /7 Clicks Group /6 Clicks Group SOURCE STATE Western Cape Western Cape Western Cape SOURCE CITY OUTWARD FDI FROM SOUTH AFRICA, 23-JUNE 212 DESTINATION COUNTRY INDUSTRY SECTOR Cape Town Lesotho Pharmaceuticals Cape Town Botswana Pharmaceuticals Cape Town Swaziland Pharmaceuticals 29/9 BMI Healthcare Gauteng Johannesburg United Kingdom Healthcare 29/3 29/2 25/5 23/12 Aspen Healthcare Afrinatural Holdings Network Healthcare Holdings Limited (Netcare) Network Healthcare Holdings Limited (Netcare) Gauteng Johannesburg UAE Pharmaceuticals Western Cape Wellington United States Pharmaceuticals Gauteng Johannesburg United Kingdom Healthcare Gauteng Johannesburg Bulgaria Healthcare SUB-SECTOR Health & personal care stores Health & personal care stores Health & personal care stores General medical & surgical hospitals Pharmaceutical preparations Pharmaceutical preparations General medical & surgical hospitals Outpatient care centres & medical & diagnostic laboratories CLUSTER Retail Trade Retail Trade Retail Trade Life sciences Life sciences Life sciences Life sciences Life sciences INDUSTRY ACTIVITY JOBS Retail Retail Retail Shared Services Centre Headquarters Sales, Marketing & Support Construction Sales, Marketing & Support TOTAL
Chart 1: Zambia's Major Trading Partners (Exports + Imports) Q4 2008 - Q4 2009. Switzernd RSA Congo DR China UAE Kuwait UK Zimbabwe India Egypt Other
Bank of Zambia us $ Million 1. INTRODUCTION This report shows Zambia s direction of merchandise trade for the fourth quarter of 2009 compared with the corresponding quarter in 2008. Revised 1 statistics,
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More information2015 Growth in data center employment continues but the workforce is changing
Published in Conjunction with MARKET BRIEFING GLOBAL DATA CENTER EMPLOYMENT 2015 2015 Growth in data center employment continues but the workforce is changing Globally, the number of people working in
More informationGlobal Pharmaceutical Trade and Contribution of India
Global Pharmaceutical Trade and Contribution of India TPR Rau. B. S 1 and Dr. Appaji P. V 2 Abstract: Trends in global pharmaceutical market in terms of sale, product category, product, regions and countries
More informationHealth Care Systems: An International Comparison. Strategic Policy and Research Intergovernmental Affairs May 2001
Health Care Systems: An International Comparison Strategic Policy and Research Intergovernmental Affairs May 21 1 Most industrialized countries have established hybrid systems in which the public sector,
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationForeign Taxes Paid and Foreign Source Income INTECH Global Income Managed Volatility Fund
Income INTECH Global Income Managed Volatility Fund Australia 0.0066 0.0375 Austria 0.0045 0.0014 Belgium 0.0461 0.0138 Bermuda 0.0000 0.0059 Canada 0.0919 0.0275 Cayman Islands 0.0000 0.0044 China 0.0000
More informationGlobal Exhibition on Services
Ministry of Commerce & Industry Global Exhibition on Services Concept Note 1 GES Concept Note Global Exhibition on Services (GES) - Concept Note The Government of India, Ministry of Commerce and Industry
More informationInternational Higher Education in Facts and Figures. Autumn 2013
International Higher Education in Facts and Figures Autumn 2013 UK Higher Education International Unit International higher education in facts and figures covers the majority of the UK higher education
More informationDigital Empowerment Foundation
1 Cost of Data Breach Study 2014 By Digital Empowerment Foundation IBM, in association with the Ponemon Institute released its 2014 Cost of Data Breach Study which aims to measure the cost that companies
More informationAustralia Life Sciences Market
Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationGlobal Privatization Trends in Healthcare and Health Insurance. Hank Kearney Global Health Access, LLC a PHM International company
Global Privatization Trends in Healthcare and Health Insurance Invest 2001 Dubai 3 April, 2001 Hank Kearney Global Health Access, LLC a PHM International company 2001 INVEST 2001 DUBAI HEALTH CARE & INSURANCE
More informationBrochure More information from http://www.researchandmarkets.com/reports/1339929/
Brochure More information from http://www.researchandmarkets.com/reports/1339929/ The 2011 World Forecasts of Machine Tools That Remove Material by Laser or Light, Photon, Ultrasonic, Electro-Discharge,
More informationI. World trade developments
I. World trade developments World merchandise exports grew by 2 per cent in value terms in 2013 while exports of commercial services increased by per cent. Key developments in 2013: a snapshot Trade data
More informationConsumer Credit Worldwide at year end 2012
Consumer Credit Worldwide at year end 2012 Introduction For the fifth consecutive year, Crédit Agricole Consumer Finance has published the Consumer Credit Overview, its yearly report on the international
More informationGCC Pharmaceutical Industry
GCC Pharmaceutical Industry First coordination meeting for the pharmaceutical industry in the GCC and Yemen Dr. Aasim Qureshi 11 April 2011 Global Pharmaceuticals Industry The pharmaceutical industry is
More informationClinical and Laboratory Practices Workshops. Helping to improve laboratory skills and the quality of care in resource-limited settings
Clinical and Laboratory Practices Workshops Helping to improve laboratory skills and the quality of care in resource-limited settings BD is committed to collaborating with governmental and non-governmental
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationSACU MERCHANDISE TRADE STATISTICS 2010 (No 2) MERCHANDISE TRADE STATISTICS 2010
SACU MERCHANDISE TRADE STATISTICS 2010 (No 2) MERCHANDISE TRADE STATISTICS 2010 TABLE OF CONTENTS 1. WORLD TRADE AND SACU... 1 2. BOTSWANA... 2 3. LESOTHO... 7 4. NAMIBIA... 12 5. SOUTH AFRICA... 16 6.
More informationEXPORT-IMPORT BANK OF INDIA: Catalysing India s Trade and Investment. July 01, 2015
EXPORT-IMPORT BANK OF INDIA: Catalysing India s Trade and Investment July 01, 2015 INDIAN ECONOMY SNAPSHOT PARAMETER FY 2010 FY 2013 FY 2014 FY 2015 GDP (current prices, US$ bn) 1365.4 1835.8 1875.9 2050.6
More informationPrivate health care cost containment and supply-side regulation. CMS presentation to the Health Portfolio Committee 2014
1 Private health care cost containment and supply-side regulation CMS presentation to the Health Portfolio Committee 2014 2 Contents Introduction Private hospital context Economic considerations Concentration
More informationHow does a venture capitalist appraise investment opportunities?
1 How does a venture capitalist appraise investment opportunities? Michael Queen - Finance Director, 3i Group plc A presentation to: 23 Pensions Convention 2 June 23 A How presentation does a venture to:
More informationExport Growth and Prospect of Floriculture in India
Export Growth and Prospect of Floriculture in India *Amitava Saha I Introduction Floriculture is an age old farming activity in India having immense potential for generating gainful self-employment among
More informationSTATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry
Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators
More informationGlobal Dynamism Index (GDI) 2013 summary report. Model developed by the Economist Intelligence Unit (EIU)
Global Dynamism Index (GDI) 2013 summary report Model developed by the Economist Intelligence Unit (EIU) What is the Global Dynamism Index (GDI)? the GDI assesses the dynamism of 60 of the world's largest
More informationSWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness
SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment
More informationAustralia s position in global and bilateral foreign direct investment
Australia s position in global and bilateral foreign direct investment At the end of 213, Australia was the destination for US$592 billion of global inwards foreign direct investment (FDI), representing
More informationList of tables. I. World Trade Developments
List of tables I. World Trade Developments 1. Overview Table I.1 Growth in the volume of world merchandise exports and production, 2010-2014 39 Table I.2 Growth in the volume of world merchandise trade
More informationMedicine price regulation the South African experience
Medicine price regulation the South African experience Dr Anban Pillay Chief Director: Health Financing and Economics National Department of Health PillaA@health.gov.za pillayanban@yahoo.com.au Tel: +27
More informationUSP CONVENTION MEMBERS BY WORLD REGION
USP CONVENTION MEMBERS BY WORLD REGION April 1, 2015 The 459 organizations listed below are Voting Organizational Members of the U.S. Pharmacopeial Convention (USP). WORLD (8) International Council of
More informationEUROPEAN. Geographic Trend Report for GMAT Examinees
2011 EUROPEAN Geographic Trend Report for GMAT Examinees EUROPEAN Geographic Trend Report for GMAT Examinees The European Geographic Trend Report for GMAT Examinees identifies mobility trends among GMAT
More informationInvesting in the United States
Investing in the United States 13 May 2015 ehealth Week 2015 Global Markets: Tools for Transatlantic Trade Kim Tuminaro Senior Trade Officer U.S. Department of State SelectUSA.gov U.S. Investment and Business
More informationI can finally afford UC without making a huge upfront investment. COO, market leader in the health care industry
1 I can finally afford UC without making a huge upfront investment. COO, market leader in the health care industry 2 Contents 01 Investing in an anytime, anywhere, connected workforce 02 On-premise, hybrid,
More informationJOB(06)/35 24 February 2006 MARKET ACCESS FOR NON-AGRICULTURAL PRODUCTS. Open Access to Enhanced Healthcare
24 February 2006 Negotiating Group on Market Access MARKET ACCESS FOR NON-AGRICULTURAL PRODUCTS Open Access to Enhanced Healthcare Communication from Singapore, the United States and Switzerland Introduction
More informationWORLD. Geographic Trend Report for GMAT Examinees
2011 WORLD Geographic Trend Report for GMAT Examinees WORLD Geographic Trend Report for GMAT Examinees The World Geographic Trend Report for GMAT Examinees identifies mobility trends among GMAT examinees
More informationThe Texas Biotechnology Industry
The Texas Biotechnology Industry 2014 Fortune 1000 company NBTY opens state-of-the-art vitamin manufacturing plant in San Antonio See Page 15 Allergan installs new production line at Waco pharmaceutical
More informationFoods With Healthy Supplements and Organics Have Room for Growth
Foods With Healthy Supplements and Organics Have Room for Growth Major Perception Gaps Across the Globe Towards Fortified and Organic Foods Popularity Held Back by Pricy Image, Niche Distribution and Credibility
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationGlobal Investing 2013 Morningstar. All Rights Reserved. 3/1/2013
Global Investing 2013 Morningstar. All Rights Reserved. 3/1/2013 World Stock Market Capitalization Year-end 2012 18.5% 9.6% United States International: Other Europe United Kingdom Japan Other Pacific
More informationInternational investment continues to struggle
FDI IN FIGURES December 2014 International investment continues to struggle Figures for the first half of 2014 point to stalled FDI flows Findings FDI fell in the first quarter of 2014 before rebounding
More informationU.S. Trade Overview, 2013
U.S. Trade Overview, 213 Stephanie Han & Natalie Soroka Trade and Economic Analysis Industry and Analysis Department of Commerce International Trade Administration October 214 Trade: A Vital Part of the
More informationHealth Insurance. Perception & Reality. Salman Rawaf MD PhD FRCP FFPH. Professor of Public Health Erbil Iraq 2-4 Feb 2011 s.rawaf@imperial.ac.
WHO Collaborating Centre Imperial College London Health Insurance Perception & Reality Salman Rawaf MD PhD FRCP FFPH Professor of Public Health Erbil Iraq 2-4 Feb 2011 s.rawaf@imperial.ac.uk Content Health
More informationThe Borderless Workforce 2011. Australia and New Zealand Research Results
The Borderless Workforce 2011 Australia and New Zealand Research Results Introduction Given the fact that neither Australia or New Zealand are facing problems, like high unemployment rates during the labour
More informationSWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY
SWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY KAPIL KUMAR*; DR. M. K. KULSHRESHTHA** *RESEARCH SCHOLAR, BHAGWANT UNIVERSITY, AJMER ** DIRECTOR, S. D. COLLEGE OF MANAGEMENT, PANIPAT ABSTRACT The global
More informationGlobal Cashew Nut Industry Report
Brochure More information from http://www.researchandmarkets.com/reports/310379/ Global Cashew Nut Industry Report Description: Cashew a native of Eastern Brazil was introduced to India by the Portuguese
More informationCANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS
CANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS Canada is a world leading location for pharmaceutical and medical device companies to conduct their clinical trials. Both publicly available
More informationThe Path Forward. International Women s Day 2012 Global Research Results
The Path Forward International Women s Day 2012 Global Research Results Research objectives Accenture conducted its global research study, The Path Forward for release on International Women s Day to gain
More informationThe big pay turnaround: Eurozone recovering, emerging markets falter in 2015
The big pay turnaround: Eurozone recovering, emerging markets falter in 2015 Global salary rises up compared to last year But workers in key emerging markets will experience real wage cuts Increase in
More informationGlobal Effective Tax Rates
www.pwc.com/us/nes Global s Global s April 14, 2011 This document has been prepared pursuant to an engagement between PwC and its Client. As to all other parties, it is for general information purposes
More informationWorld Consumer Income and Expenditure Patterns
World Consumer Income and Expenditure Patterns 2014 14th edi tion Euromonitor International Ltd. 60-61 Britton Street, EC1M 5UX TableTypeID: 30010; ITtableID: 22914 Income Algeria Income Algeria Income
More informationPrivate Cloud for Every Organization
white paper Private Cloud for Every Organization Leveraging the community cloud As more organizations today seek to gain benefit from the flexibility and scalability of cloud environments, many struggle
More informationopinion piece Meeting the Challenges of Supplier Relations in a Multisourcing Environment
opinion piece Meeting the Challenges of Supplier Relations in a Multisourcing Environment New approaches and skills are required to effectively manage the increased volume and complexity of relationships
More informationSpain: Medical equipment and healthcare technology sector
Spain: Medical equipment and healthcare technology sector ICEX sector reports one two three four five six Sector definition Spanish sector overview Foreign trade Leading companies Trade fairs Useful addresses
More informationDividends Tax: Summary of withholding tax rates per South African Double Taxation Agreements currently in force Version: 2 Updated: 2012-05-22
Dividends Tax: Summary of withholding tax rates per South African Double Taxation Agreements currently in force Version: 2 Updated: 2012-05-22 Note: A summary of the rates and the relevant provisions relating
More information[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)]
[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)] Executive Summary Stem Cells have a remarkable ability to develop in various body cells of a human. These occur in the earliest stages
More informationNormand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada
Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug
More informationUBS 9th annual financial services conference. The quest for positive jaws
UBS 9th annual financial services conference The quest for positive jaws Metropolitan s vision Creating prosperity for Africa s people Represents its ideal positioning in the eyes of its customers Is an
More informationThe Role of Banks in Global Mergers and Acquisitions by James R. Barth, Triphon Phumiwasana, and Keven Yost *
The Role of Banks in Global Mergers and Acquisitions by James R. Barth, Triphon Phumiwasana, and Keven Yost * There has been substantial consolidation among firms in many industries in countries around
More informationA new ranking of the world s most innovative countries: Notes on methodology. An Economist Intelligence Unit report Sponsored by Cisco
A new ranking of the world s An Economist Intelligence Unit report Sponsored by Cisco Economist Intelligence Unit Limited 2009 A new ranking of the world s Preface In April 2009, the Economist Intelligence
More informationIMD World Talent Report. By the IMD World Competitiveness Center
2014 IMD World Talent Report By the IMD World Competitiveness Center November 2014 IMD World Talent Report 2014 Copyright 2014 by IMD: Institute for Management Development, Lausanne, Switzerland For further
More informationSecond Quarter and First Half 2015 Trading Update
Second Quarter and First Half 2015 Trading Update Trading Performance Year-on-Year Gross Profit Reported ( m) Constant 2015 2014 % % Q2 145.3 137.1 +6.0% +10.6% H1 281.0 263.7 +6.6% +10.8% Q2 Gross Profit
More informationEMEA BENEFITS BENCHMARKING OFFERING
EMEA BENEFITS BENCHMARKING OFFERING COVERED COUNTRIES SWEDEN FINLAND NORWAY ESTONIA R U S S I A DENMARK LITHUANIA LATVIA IRELAND PORTUGAL U. K. NETHERLANDS POLAND BELARUS GERMANY BELGIUM CZECH REP. UKRAINE
More information2011 ICT Facts and Figures
The World in 211 ICT Facts and Figures One third of the world s population is online 45% of Internet users below the age of 25 Share of Internet users in the total population Users, developed Using Internet:
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More information360 o View of. Global Immigration
360 o View of Global Immigration In a fast moving global economy, remaining compliant with immigration laws, being informed and in control is more challenging than ever before. We are a globally linked
More informationopinion piece Eight Simple Steps to Effective Software Asset Management
opinion piece Eight Simple Steps to Effective Software Asset Management Contents Step 1: Collate your licence agreements 01 Step 2: Determine your actual licence position 01 Step 3: Understand your existing
More informationContact Centre Integration Assessment
Contact Centre Integration Assessment How well are your business objectives aligned with the right contact centre technologies? Knowing how the technology in your contact centre supports service delivery
More informationGlobal growth rates Macroeconomic indicators CEDIGAZ Reference Scenario
Medium and Long Term Natural Gas Outlook CEDIGAZ February 215 Global growth rates Macroeconomic indicators CEDIGAZ Reference Scenario 4 3 %/year 199-213 213-235 6 Main consuming markets - %/year (213-235)
More informationSybase Solutions for Healthcare Adapting to an Evolving Business and Regulatory Environment
Sybase Solutions for Healthcare Adapting to an Evolving Business and Regulatory Environment OVERVIEW Sybase Solutions for Healthcare Adapting to an Evolving Business and Regulatory Environment Rising medical
More informationAgeing OECD Societies
ISBN 978-92-64-04661-0 Trends Shaping Education OECD 2008 Chapter 1 Ageing OECD Societies FEWER CHILDREN LIVING LONGER CHANGING AGE STRUCTURES The notion of ageing societies covers a major set of trends
More informationI. World trade developments
I. World trade developments The value of world merchandise exports increased by 20 per cent in 2011 while exports of commercial services grew by 11 per cent. Key developments in 2011: a snapshot Trade
More informationSoftware-as-a-service Delivery: The Build vs. Buy Decision
white paper Software-as-a-service Delivery: The Build vs. Buy Decision Introduction In order to deliver software on-demand, companies must either build and manage an infrastructure capable of supporting
More informationMaximizing Your Value-Add: Conducting a Best-in-Class Market Analysis
Maximizing Your Value-Add: Conducting a Best-in-Class Market Analysis Dr. George L. Harris, President Calyptus Consulting Group, Inc. 781-674-0041; gharris@calyptusgroup.com 93 rd Annual International
More informationGovernance, Risk and Compliance Assessment
Governance, Risk and Compliance Assessment Information security is a pervasive business requirement and one that no organisation can afford to get wrong. If it s not handled properly, your business could
More information4. ROLE OF PRIVATE SECTOR IN HEALTH CARE IN INDIA CHALLENGES, OPPORTUNITIES & STARTEGIES
4. ROLE OF PRIVATE SECTOR IN HEALTH CARE IN INDIA CHALLENGES, OPPORTUNITIES & STARTEGIES * G K Lath Type of Health Care Systems 3 Basic Types Type Finance Sector Delivery Sector Examples I Private Private
More informationAppendix 1: Full Country Rankings
Appendix 1: Full Country Rankings Below please find the complete rankings of all 75 markets considered in the analysis. Rankings are broken into overall rankings and subsector rankings. Overall Renewable
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationSubmission by the Irish Pharmacy Union to the Department of Health on the Scope for Private Health Insurance to incorporate Additional Primary Care
Submission by the Irish Pharmacy Union to the Department of Health on the Scope for Private Health Insurance to incorporate Additional Primary Care Services January 2015 1 IPU Submission to the Department
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationLIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
More informationHONG KONG RIGHT PLACE RIGHT TIME RIGHT NOW
HONG KONG RIGHT PLACE RIGHT TIME RIGHT NOW European Investment in China via Hong Kong Charles Ng Associate Director-General of Investment Promotion 22 May 2012 Agenda Changing Trends in the type of companies
More informationUK Television Exports FY 2014/2015
UK Television Exports FY 2014/2015 Page 1 of 5 The annual UK Television Exports Survey highlights the popularity of UK programming abroad by collecting revenue figures relating to the international activity
More informationDSV Air & Sea, Inc. Aerospace Sector. DSV Air & Sea, Inc. Aerospace
DSV Air & Sea, Inc. Aerospace Sector DSV Air & Sea, Inc. Aerospace Introduction to DSV DSV is a global supplier of transport and logistics services. We have offices in more than 70 countries and an international
More informationBANK FOR INTERNATIONAL SETTLEMENTS P.O. BOX, 4002 BASLE, SWITZERLAND
BANK FOR INTERNATIONAL SETTLEMENTS P.O. BOX, 4002 BASLE, SWITZERLAND PRESS RELEASE CENTRAL BANK SURVEY OF FOREIGN EXCHANGE AND DERIVATIVES MARKET ACTIVITY IN APRIL 1998: PRELIMINARY GLOBAL DATA The BIS
More informationPharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
More informationIn 2012, GNP in constant prices increased by 1.8% compared with 2011.
8 Economy In 2012, GNP in constant prices increased by 1.8% compared with 2011. The building and construction sector fell by 7.7% in value added terms in 2012 compared to 2011. Manufacturing industry decreased
More informationThe rise of the cross-border transaction. Grant Thornton International Business Report 2013
The rise of the cross-border transaction Grant Thornton International Business Report 2013 Foreword MIKE HUGHES GLOBAL SERVICE LINE LEADER MERGERS & ACQUISITIONS GRANT THORNTON INTERNATIONAL LTD When reflecting
More informationVendor Query Portal VENDOR QUERY PORTAL In our continued endeavor to simplify our processes and pay Suppliers on time, A webbased Invoice and Payment tracking tool -Vendor Query Portal (VQP) is now available
More informationThe value of accredited certification
Certified Once Accepted Everywhere The value of accredited certification Survey Report Published May 212 In 21/11, the IAF carried out a global survey to capture market feedback on the value of certification.
More informationGLOBAL HRMONITOR NEW DIMENSIONS IN ONLINE HR INFORMATION TALENT HEALTH RETIREMENT INVESTMENTS
GLOBAL HRMONITOR NEW DIMENSIONS IN ONLINE HR INFORMATION TALENT HEALTH RETIREMENT INVESTMENTS DISCOVER MERCER S GLOBAL HRMONITOR ABOUT GLOBAL HRMONITOR Mercer s Global HRMonitor is a single-source, web-based
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)32 DAF/COMP/GF/WD(2014)32 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 30-Jan-2014 English
More informationIntroduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
More informationHealth Innovation. Innovation for health includes the. diagnostics and medical devices, as
BIO-INNOVATION Health Innovation Innovation for health includes the development of new drugs, vaccines, diagnostics and medical devices, as well as new techniques in process engineering and manufacturing,
More informationPharmaceutical and medical commodity research is profiling discipline which aims at training employees of the pharmacy to perform professional
Pharmaceutical and medical commodity research is profiling discipline which aims at training employees of the pharmacy to perform professional merchandising functions related to providing medical institutions
More informationThe Impact of The European Crisis on Travel To and From Europe and China & Asia-Pacific
The Impact of The European Crisis on Travel To and From Europe and China & Asia-Pacific A Report by Research For Travel Ltd July 2012 Research For Travel Ltd The Impact of The European Crisis on Travel
More informationMALTA TRADING COMPANIES IN MALTA
MALTA TRADING COMPANIES IN MALTA Trading companies in Malta 1. An effective jurisdiction for international trading operations 410.000 MALTA GMT +1 Located in the heart of the Mediterranean, Malta has always
More informationHong Kong Poised to be the Asia s Biotechnology Hub
Think Asia, think Hong Kong - London 13-09-2011 www.hkbio.org.hk BioTech at Science Park Your Safe and Fast Track to China Hong Kong Poised to be the Asia s Biotechnology Hub Albert Cheung Hoi Yu, Ph.D.
More informationInternational Education in the Comox Valley: Current and Potential Economic Impacts
International Education in the Comox Valley: Current and Potential Economic Impacts FINAL REPORT March 2012 Prepared by: Vann Struth Consulting Group Inc. Vancouver, BC www.vannstruth.com Prepared for:
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More information